AVRO vs. CDTX, GNTA, ENTX, ALGS, LENZ, TSBX, QNCX, OKYO, IKNA, and CYTH
Should you be buying AVROBIO stock or one of its competitors? The main competitors of AVROBIO include Cidara Therapeutics (CDTX), Genenta Science (GNTA), Entera Bio (ENTX), Aligos Therapeutics (ALGS), LENZ Therapeutics (LENZ), Turnstone Biologics (TSBX), Quince Therapeutics (QNCX), OKYO Pharma (OKYO), Ikena Oncology (IKNA), and Cyclo Therapeutics (CYTH). These companies are all part of the "biological products, except diagnostic" industry.
AVROBIO (NASDAQ:AVRO) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
Cidara Therapeutics received 266 more outperform votes than AVROBIO when rated by MarketBeat users. Likewise, 70.19% of users gave Cidara Therapeutics an outperform vote while only 66.93% of users gave AVROBIO an outperform vote.
In the previous week, AVROBIO had 1 more articles in the media than Cidara Therapeutics. MarketBeat recorded 6 mentions for AVROBIO and 5 mentions for Cidara Therapeutics. Cidara Therapeutics' average media sentiment score of 0.94 beat AVROBIO's score of 0.69 indicating that Cidara Therapeutics is being referred to more favorably in the news media.
AVROBIO presently has a consensus price target of $2.00, suggesting a potential upside of 62.60%. Cidara Therapeutics has a consensus price target of $71.25, suggesting a potential upside of 485.94%. Given Cidara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cidara Therapeutics is more favorable than AVROBIO.
AVROBIO has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
AVROBIO has higher earnings, but lower revenue than Cidara Therapeutics.
62.6% of AVROBIO shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 9.2% of AVROBIO shares are owned by insiders. Comparatively, 7.4% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
AVROBIO has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -33.19%. AVROBIO's return on equity of -48.42% beat Cidara Therapeutics' return on equity.
Summary
Cidara Therapeutics beats AVROBIO on 9 of the 16 factors compared between the two stocks.
Get AVROBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
